Estimates of COVID‐19 deaths in Mainland China after abandoning zero COVID policy

Author:

Ioannidis John P. A.123ORCID,Zonta Francesco4,Levitt Michael5

Affiliation:

1. Meta‐Research Innovation Center at Stanford (METRICS) Stanford University Stanford California USA

2. Department of Medicine Stanford University Stanford California USA

3. Department of Epidemiology and Population Health Stanford University Stanford California USA

4. Shanghai Institute for Advanced Immunochemical Studies ShanghaiTech University Shanghai China

5. Department of Structural Biology Stanford University Stanford California USA

Abstract

AbstractBackgroundChina witnessed a surge of Omicron infections after abandoning ‘zero COVID’ strategies on 7 December 2022. The authorities report very sparse deaths based on very restricted criteria, but massive deaths are speculated.MethodsWe aimed to estimate the COVID‐19 fatalities in Mainland China until summer 2023 using the experiences of Hong Kong and of South Korea in 2022 as prototypes. Both these locations experienced massive Omicron waves after having had very few SARS‐CoV‐2 infections during 2020–2021. We estimated age‐stratified infection fatality rates (IFRs) in Hong Kong and South Korea during 2022 and extrapolated to the population age structure of Mainland China. We also accounted separately for deaths of residents in long‐term care facilities in both Hong Kong and South Korea.ResultsInfection fatality rate estimates in non‐elderly strata were modestly higher in Hong Kong than South Korea and projected 987,455 and 619,549 maximal COVID‐19 deaths respectively, if the entire China population were infected. Expected COVID‐19 deaths in Mainland China until summer 2023 ranged from 49,962 to 691,219 assuming 25–70% of the non‐elderly population being infected and variable protection of elderly (from none to three‐quarter reduction in fatalities). The main analysis (45% of non‐elderly population infected and fatality impact among elderly reduced by half) estimated 152,886–249,094 COVID‐19 deaths until summer 2023. Large uncertainties exist regarding potential changes in dominant variant, health system strain and impact on non‐COVID‐19 deaths.ConclusionsThe most critical factor that can affect total COVID‐19 fatalities in China is the extent to which the elderly can be protected.

Funder

National Institutes of Health

Publisher

Wiley

Subject

Clinical Biochemistry,Biochemistry,General Medicine

Reference43 articles.

1. Institute for Health Metric and Evaluation report inhttps://1drv.ms/b/s!AuOyHP_aTIy72tRSHCDtJqOI5d_T9w?e=X2SMBb. Accessed December 26 2022.

2. SridharD.https://www.theguardian.com/commentisfree/2022/dec/21/china‐covid‐surge‐vaccination‐data‐infected Guardian Accessed December 26 2022.

3. BradsherK ChienAC DongJ.https://www.nytimes.com/2022/12/23/world/asia/china‐covid‐death‐toll.html New York Times Accessed December 26 2022.

4. https://www.airfinity.com/articles/china‐risks‐between‐1‐3‐and‐2‐1‐million‐deaths‐if‐it‐ends‐its‐zero‐covid. Accessed December 26 2022.

5. Over- and under-estimation of COVID-19 deaths

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3